In tumor-implanted mice, the co-injection of Nefmut –based vectors elicited a CD8+ T cell immune response much higher than that elicited in mice injected with vectors expressing the HPV16 products alone and, consistently, the antitumor effect was far more effective. The gene discussed is CD8A; the disease is neoplasm.